Oral verapamil does not affect glucose tolerance in non-diabetics.
Verapamil, a calcium antagonist used to treat angina pectoris, inhibits insulin release in vitro and, when administered intravenously to humans, decreases glucose tolerance. Oral verapamil, 120 mg/day for 1 week increasing thereafter to 240 mg/day in divided doses, was given to nine non-diabetic patients with angina pectoris for 4 weeks. The glucose and insulin responses to a standard glucose load showed no significant difference before and after verapamil. Oral verapamil in the doses used in this study had no significant effect on glucose tolerance in non-diabetics.
D000328:Adult; D000787:Angina Pectoris / Q000188:drug therapy / Q000378:metabolism; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014700:Verapamil / Q000494:pharmacology* / Q000627:therapeutic use
D014700:Verapamil